FDA wants to educate providers and patients on biosimilars as more of the products enter the market, but funding may only be available for a targeted campaign.
Agency officials plan to provide material for webinars and presentations, as well as work with professional societies and other groups...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?